{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:16:11Z","timestamp":1788279371111,"version":"build-2803163510"},"reference-count":22,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Oncol.","Current Oncology"],"abstract":"<jats:p>Background: Retained totally implantable venous access ports (TIVAPs) pose a clinical management challenge after completion of intravenous anticancer therapy, particularly when future treatment needs remain uncertain. We aimed to characterize longitudinal post-treatment TIVAP trajectories after a day-90 conditional landmark, with elective removal prespecified as the primary first event. Methods: This retrospective cohort study included patients who were alive and event-free, retained the original TIVAP, had no documented TIVAP-related indication requiring removal, and had documented clinical and TIVAP status at day 90. Elective removal was the primary event; TIVAP reactivation, complication-related removal, and network-documented death were competing events. Results: Among 1406 patients, the 12-month cumulative incidence was 34.3% (95% confidence interval [CI], 31.4\u201337.1) for elective removal, 10.1% (95% CI, 8.2\u201311.9) for reactivation, 4.1% (95% CI, 3.0\u20135.3) for complication-related removal, and 1.0% (95% CI, 0.5\u20131.6) for network-documented death. During 1164.9 patient-years, 9978 maintenance-related patient-date encounters were recorded. In the assessed subcohort (n = 1319), 69.2% of assessments indicated willingness to choose a TIVAP again for similar future treatment, 64.4% indicated willingness to recommend TIVAP use, and 26.0% recorded a preference for earlier removal. Conclusions: Retained TIVAPs followed heterogeneous post-treatment courses, including elective removal, subsequent reuse, and continued retention requiring maintenance. These findings describe observed management patterns; they do not establish the comparative effectiveness of retention versus removal or identify an optimal removal time, and they support a prospective evaluation of structured reassessment pathways.<\/jats:p>","DOI":"10.3390\/curroncol33090525","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:08:43Z","timestamp":1788275323000},"page":"525","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-Treatment Trajectories of Retained Totally Implantable Venous Access Ports After Anticancer Therapy: A Conditional Landmark Cohort Study"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-8056","authenticated-orcid":false,"given":"Zeyang","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Interventional Vascular Surgery, Peking University First Hospital, Beijing 100034, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Feicheng People\u2019s Hospital, Feicheng 271600, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/COC.0000000000000361","article-title":"Totally implantable venous access devices: A review of complications and management strategies","volume":"40","author":"Tabatabaie","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_2","first-page":"81","article-title":"Totally implantable venous access ports: A prospective long-term study of early and late complications in adult patients with cancer","volume":"26","author":"Voog","year":"2018","journal-title":"Support. Care Cancer"},{"key":"ref_3","first-page":"775","article-title":"Patient-reported outcome and experience measures among patients with central venous access devices: A systematic review","volume":"32","author":"Larsen","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/11297298251340461","article-title":"Port REMoval Outcomes (PREMO) study: Patients\u2019 experiences with a totally implantable venous access device: A questionnaire at device removal","volume":"27","author":"Goossens","year":"2026","journal-title":"J. Vasc. Access"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e026077","DOI":"10.1136\/bmjopen-2018-026077","article-title":"Patient acceptability of three different central venous access devices for the delivery of systemic anticancer therapy: A qualitative study","volume":"9","author":"Ryan","year":"2019","journal-title":"BMJ Open"},{"key":"ref_6","unstructured":"Professional Committee of Interventional Oncology, Chinese Anti-Cancer Association, Professional Committee on Minimally Invasive Intervention, World Association of Chinese Oncology, and Professional Committee of Intervention, Beijing Association of Oncology (2025). Clinical practice and quality control guidelines for totally implantable venous access ports in cancer patients (2024). J. Sichuan Univ. Med. Sci. Ed., 56, 400\u2013410."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1177\/1129729820950998","article-title":"Prolonging the flush-lock interval of totally implantable venous access ports in patients with cancer: A systematic review and meta-analysis","volume":"22","author":"Wu","year":"2021","journal-title":"J. Vasc. Access"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e1438","DOI":"10.1200\/OP.22.00060","article-title":"Is there a relationship between frequency of port-care maintenance and related complications in patients with cancer?","volume":"18","author":"Lang","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wang, Y., Tian, H., Chen, X., Zhang, J., Wang, L., Fan, H., Zhang, Y., Qi, X., Hu, S., and Yang, Y. (2022). Safety and feasibility assessment of extending the flushing interval in totally implantable venous access port flushing during the non-treatment stage for patients with breast cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1021488"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1177\/11297298241282822","article-title":"Safety of 3-month flushing interval for prevention of occlusion in totally implantable venous access ports: An analysis focused on intraluminal clots","volume":"26","author":"Yang","year":"2025","journal-title":"J. Vasc. Access"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Xi, Y., Zhu, X., and Ni, W. (2026). Barriers to continuity of outpatient infusion-port maintenance among patients with cancer: A single-center cross-sectional study in China. Front. Public Health, 14.","DOI":"10.3389\/fpubh.2026.1877650"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/curroncol28010039","article-title":"Utilization and complications of central venous access devices in oncology patients","volume":"28","author":"Akhtar","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Su, J., Liu, L., Xie, Y., and Wang, J. (2024). Complications associated with the removal of totally implantable venous access devices: A retrospective analysis of 4,954 breast cancer patients in a single institution. BMC Surg., 24.","DOI":"10.1186\/s12893-024-02630-w"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/11297298251335416","article-title":"Port REMoval Outcomes (PREMO) study: A pilot study for functional, microbial, radiological, and macroscopic assessment of totally implantable venous access devices","volume":"27","author":"Douchy","year":"2026","journal-title":"J. Vasc. Access"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejon.2010.11.007","article-title":"The late complications of totally implantable central venous access ports: The results from an Italian multicenter prospective observation study","volume":"15","author":"Rasero","year":"2011","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejso.2008.01.020","article-title":"An 11-year retrospective study of totally implanted central venous access ports: Complications and patient satisfaction","volume":"35","author":"Ignatov","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_17","first-page":"3531","article-title":"Availability of totally implantable venous access devices in cancer patients is high in the long term: A seven-year follow-up study","volume":"29","author":"Tumay","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s13193-025-02466-7","article-title":"Indian expert consensus on the selection of vascular access devices in oncology patients","volume":"17","author":"Somashekhar","year":"2025","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"v152","DOI":"10.1093\/annonc\/mdv296","article-title":"Central venous access in oncology: ESMO Clinical Practice Guidelines","volume":"26","author":"Sousa","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1200\/JCO.2012.45.5733","article-title":"Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Schiffer","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The STROBE statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Benchimol, E.I., Smeeth, L., Guttmann, A., Harron, K., Moher, D., Petersen, I., S\u00f8rensen, H.T., von Elm, E., Langan, S.M., and RECORD Working Committee (2015). The RECORD statement. PLoS Med., 12.","DOI":"10.1371\/journal.pmed.1001885"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/525\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:21:42Z","timestamp":1788276102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/9\/525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["curroncol33090525"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33090525","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}